[Parameters for the measurement of long-term effects of an orally administered drug in organic and functional circulatory disorders. Preliminary communication].
D000328:Adult; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004087:Dihydroergotamine / Q000627:therapeutic use; D004088:Dihydroergotoxine / Q000627:therapeutic use; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004338:Drug Combinations; D046948:Secologanin Tryptamine Alkaloids; D014665:Vasodilator Agents; D004088:Dihydroergotoxine; D004087:Dihydroergotamine
Parameter zur Messung der Langzeitwirkung eines oral verabfolgten Medikamentes bei organischen und funktionellen Durchblutungsstörungen. Vorläufige Mitteilung